Do you want to read an article? Please log in or register.
Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trial
Lung, Respiratory and Thoracic Cancer
